Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. (30th April 2019)

• Record Type: Journal Article
• Authors: Mistraletti, Giovanni; Paroni, Rita; Umbrello, Michele; Moro Salihovic, Bedrana; Coppola, Silvia; Froio, Sara; Finati, Elena; Gasco, Paolo; Savoca, Adriana; Manca, Davide; Chiumello, Davide; Reiter, Russel J.; Iapichino, Gaetano
• Is Part Of: Clinical endocrinology. Volume 91:Number 1(2019)
• Page Start: 209
• Page End: 218
• Publication Date: 2019-04-30
• Subjects: critically ill patients -- lipid nanovector encapsulation -- melatonin -- microemulsion -- transdermal absorption; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.13993
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Background and objectives: Critically ill patients present reduced endogenous melatonin blood levels, and they might benefit from its exogenous supplementation. The aim of this research was to evaluate the feasibility of different routes of administration and drug formulations of melatonin. The efficiency of absorption was assessed as well as the adequacy in achieving and maintaining the physiological nocturnal blood peak. Methods: Twenty‐one high‐risk critically ill patients were randomly assigned to receive melatonin either: (a) per os, as a standard tablet (ST‐OS), (b) per os, as a suspension in solid lipid nanoparticles (SLN‐OS) or c) transdermal (TD), by applying a jellified melatonin microemulsion (μE) on the skin (μE‐TD). SLN‐OS and μE‐TD were lipid‐based colloidal systems. The endogenous melatonin blood values were observed for 24 hours; subsequently, melatonin 3 mg was administered and pharmacokinetics was studied for 24 hours further. Results: In both groups that received ST‐OS and SLN‐OS, the median time‐to‐peak blood concentration was 0.5 hours; however, the area under the curve (AUC) after administration of SLN‐OS was significantly higher than after ST‐OS (157386 [65732‐193653] vs 44441 [22319‐90705] pg/mL*hours, P = 0.048). μE‐TD presented a delayed time‐to‐peak blood concentration (4 hours), a lower bioavailability (AUC: 3142 [1344‐14573] pg/mL*hours) and reached pharmacological peak concentration (388 [132‐1583] pg/mL). Conclusions: SLN‐melatonin enterally administered offers favourable pharmacokinetics in critically ill patients, with higher bioavailability with respect to the standard formulation; μE‐TD provided effective pharmacological blood levels, with a time‐concentration profile more similar to the physiological melatonin pattern.